SAN ANTONIO — Researchers developed an ASCVD risk score that was shown to estimate residual ASCVD risk among adults with prior CVD who are on statin therapy.
The risk model for predicting 5-year residual ASCVD risk in this population identifies older age, male sex, no alcohol use, positive family history, diabetes, increased lipoprotein(a), homocysteine and serum creatinine as significant contributors to risk prediction, Yanglu Zhao, MD, MS, PhD candidate of epidemiology at UCLA, said during a presentation at the American Society for Preventive Cardiology Congress on CVD Prevention.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.